Loading…
Also known as Glucosamine sulfate, Glucosamine HCl
Amino sugar naturally present in cartilage, used as a substrate for glycosaminoglycan synthesis; sulfate-bound formulations have the strongest trial evidence for slowing osteoarthritis symptom progression over months of use.
We link to relevant studies and leave interpretation to you and your healthcare professional.
Number of audited published findings for Glucosamine by condition. Drill into a pair page for the full breakdown.
Where people report using it and what trials suggest
Common claims the trials do not support
Joint-health staple whose rigorous trials have not confirmed structural or symptom benefits beyond placebo for most users.
Safety notes: Shellfish-derived forms are allergen-refined; diabetics should monitor glucose with high doses.
Evidence grades reflect study quality and consistency, not marketing claims.
Summaries of published trial results for this compound, grouped by condition. Numbers are reported exactly as the researchers published them — we never calculate or convert.
How to read this table
In short: benefit is what was observed; evidence is how much you should trust the observation. A “Benefit seen” tag on a weak study counts for far less than the same tag on a meta-analysis.
| Outcome measured | What trials found | Effect size | People studied | Duration | Type of evidence | Study |
|---|---|---|---|---|---|---|
| Adverse events (6 months) | Adverse events were low and similarly distributed for CS+GH vs celecoxib over 6 months.No clear benefit | no number reported | 606 | 6 months | RCT · 2016 | PMID 25589511 |
| Joint swelling and effusion (6 months) | Joint swelling and effusion reductions were similar for CS+GH vs celecoxib, both greater than 50%.Unclear | >50% | 606 | 6 months | RCT · 2016 | PMID 25589511 |
| OMERACT-OARSI response criteria (6 months) | 79.7% of CS+GH patients vs 79.2% of celecoxib patients met OMERACT-OARSI response criteria at 6 months. |
Associated conditions and community-reported outcomes, wrapped together on one page. Aggregates appear only once enough reports arrive.
How this compound is sold in the UK, and where our readers typically find it.
Retailer search links — we may earn commission on purchases at no cost to you. Commission never affects our evidence ratings.
| 79.7% |
| 606 |
| 6 months |
| RCT · 2016 |
| PMID 25589511 |
| WOMAC pain (6 months) | CS+GH was non-inferior to celecoxib for WOMAC pain reduction (50.1% vs 50.2%) after 6 months (p=0.92). (-22.0 to 19.8; p=0.92)Unclear | -1.11 | 606 | 6 months | RCT · 2016 | PMID 25589511 |